Page 15 - 09 EMA

ndication

onventional therapy including a corticosteroid, an immunomodulator
and primary nutrition therapy; or who are intolerant to or have
ontraindications for such therapies. Infliximab has been studied only in
ombination with conventional immunosuppressive therapy.
Ulcerative colitis
nflectra is indicated for treatment of moderately to severely active
ulcerative colitis in adult patients who have had an inadequate response
o conventional therapy including corticosteroids and 6mercaptopurine
6MP) or azathioprine (AZA), or who are intolerant to or have medical
ontraindications for such therapies.
Paediatric ulcerative colitis
nflectra is indicated for treatment of severely active ulcerative colitis in
hildren and adolescents agedsix to 17years, who have had an
nadequate response to conventional therapy including corticosteroids
and 6MP or AZA, or who are intolerant to or have medical
ontraindications for such therapies.
Ankylosing spondylitis
nflectra is indicated for treatment of severe, active ankylosing
pondylitis in adult patients who have responded inadequately to
onventional therapy.
Psoriatic arthritis
nflectra is indicated for treatment of active and progressive psoriatic
arthritis in adult patients when the response to previous DMARD
herapy has been inadequate.
nflectra should be administered:

 in combination with methotrexate;
 or alone in patients who show intolerance to methotrexate or for

whom methotrexate is contraindicated.
nfliximab has been shown to improve physical function in patients with
psoriatic arthritis, and to reduce the rate of progression of peripheral
oint damage as measured by Xray in patients with polyarticular
ymmetrical subtypes of the disease.

-8-